Modulatory effects of plasma and colonic milieu of patients with ulcerative colitis on neutrophil reactive oxygen species production in presence of a novel antioxidant, rebamipide
Modulatory effects of plasma and colonic milieu of patients with ulcerative colitis on neutrophil reactive oxygen species production in presence of a novel antioxidant, rebamipide
复制标题
DOI：
10.1023/a:1015382800434
复制
发表时间：
2002-06-01
影响因子：
3.1
通讯作者：
Banan, A
中科院分区：
文献类型：
--
作者：
Farhadi, A;Keshavarzian, A;Banan, A
瑞巴派特可保护胃肠粘膜完整性免受活性氧 (ROS) 的影响。评估了在对照受试者和溃疡性结肠炎 (UC) 受试者的血浆和直肠透析液 (RD) 存在下瑞巴派特对 PMN 产生 ROS 的能力的影响。我们招募了 6 名健康志愿者来获取 PMN、对照血浆和对照 RD，以及 6 名非活动性 UC 患者来获取血浆和 RD。使用 fMLP 激活 PMN，并通过荧光微孔板测定 (DCFD) 测量 ROS。瑞巴派特显着抑制中性粒细胞呼吸爆发达 45%。来自对照受试者和 UC 患者的血浆显着减弱了 fMLP 诱导的呼吸爆发。然而，UC患者的血浆的抑制性明显低于对照受试者的血浆。对照受试者的 RD 显着减弱了 fMLP 诱导的呼吸爆发，而 UC 患者的 RD 则没有。在从对照组和 UC 患者获得的血浆或 RD 存在下，瑞巴派特保持其抗氧化作用。总之，UC 患者血浆和 RD 抑制作用的部分丧失可能导致 UC 中氧化诱导的组织损伤，并且瑞巴派特的抗氧化特性并未受到 UC 患者生物环境的阻碍。
Rebamipide protects gastrouintestinal mucosal integrity against reactive oxygen species (ROS). The effect of rebamipide on the capability of PMNs to produce ROS in the presence of plasma and rectal dialysates (RD) of control and ulcerative colitis (UC) subjects was evaluated. We recruited six healthy volunteers for obtaining PMNs, control plasma, and control RD and six patients with inactive UC for obtaining plasma and RD. PMNs were activated using fMLP, and ROS was measured by fluorescent microplate assay (DCFD). Rebamipide significantly inhibited the neutrophil respiratory burst by 45%. Plasma from both control subjects and UC patients significantly blunted the fMLP-induced respiratory burst. However, the plasma of the UC patients was significantly less inhibitory than the plasma of control subjects. RD from control subjects significantly blunted the fMLP-induced respiratory burst while, RD from patients with UC did not. Rebamipide maintained its antioxidant effects in the presence of plasma or RD obtained from both controls and UC patients. In conclusion, partial loss of the inhibitory effects of plasma and RD in patients with UC may contribute to oxidative-induced tissue damage in UC and rebamipide antioxidant properties were not hampered by the biological milieu of patients with UC.